论文部分内容阅读
目的了解慢型克山病患者血清中αB晶体蛋白的表达情况,探索其是否可以做为克山病生物标志物的一种。方法选择慢型克山病患者和对照各40人。对其血清采用酶联免疫吸附法检测αB晶体蛋白(heat shock protein B5,HSPB5)、N末端B型利钠肽原(NT-pro BNP)、骨桥蛋白(osteopontin,OPN)的表达量,丙二醛(malondialdehyde,MDA)采用比色法测定。结果αB晶体蛋白在病例组中的表达水平(368.51±231.61)低于对照组(486.06±289.08);NT-pro BNP在病例组的表达水平(11 570.61±3 969.37)高于对照组(9 403.79±5 012.81);MDA表达量病例组(5.11±3.49)高于对照组(3.43±2.80);OPN表达量在病例组(37.53±23.10)和对照组(36.59±34.99)间无差异。结论病例组αB晶体蛋白的表达量低于对照组;αB晶体蛋白有可能是克山病心肌损伤的一种心脏标志物。
Objective To understand the expression of αB crystallin in serum of patients with chronic Keshan disease and explore whether it can be used as a biomarker of Keshan disease. Methods Forty patients with chronic Keshan disease and 40 controls were enrolled. Serum levels of heat shock protein B5 (HSPB5), NT-pro BNP and osteopontin (OPN) were detected by enzyme-linked immunosorbent assay (ELISA) Malondialdehyde (MDA) was measured by colorimetry. Results The expression level of α-B protein in the case group was lower than that in the control group (368.51 ± 231.61) (486.06 ± 289.08). The expression level of NT-pro BNP in the case group (11 570.61 ± 3 969.37) was higher than that of the control group (9 403.79) ± 5 012.81). The expression of OPN in the case group (5.11 ± 3.49) was higher than that in the control group (3.43 ± 2.80). There was no difference in OPN expression between the case group (37.53 ± 23.10) and the control group (36.59 ± 34.99). Conclusion The expression of αB crystal protein in case group is lower than that in control group. ΑB crystal protein may be a cardiac marker of myocardial injury in Keshan disease.